Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01110551 · ClinicalTrials.gov registry record · Phase 1
Tetravalent Chimeric Dengue Vaccine Trial
A Phase 1 study of Dengue, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT01110551: Completed Phase 1 study of Dengue, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT01110551 is a Phase 1 study of Dengue that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 72 participants, below the 3,973-participant average among 9 other Dengue trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01110551, a Phase 1 study of Dengue, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the safety and immune response to a live attenuated dengue vaccine that could protect people against all 4 types of dengue virus. Live attenuated means that while this vaccine contains 4 live dengue viruses the viruses have been attenuated (weakened) so as not to cause dengue disease in people. Dengue virus is spread to people by mosquitoes and can cause sickness and even death. Seventy-two subjects between the ages of 18-45 years old will be enrolled in this research study at Saint Louis University Center for Vaccine Development. Participants will be randomly assigned to 1 of 4 groups to receive 2 doses of the study vaccine or placebo (inactive substance). Study procedures include: maintaining a diary to record temperature and side effects, physical exam, electrocardiogram (ECG) (measures the activity of the heart), and blood samples. Participants will be involved in study related procedures for about 10 months.
Conditions Studied
Interventions
- DRUG Placebo (SC)
- DRUG Placebo (ID)
- BIOLOGICAL Modified Live Tetravalent Chimeric Dengue Vaccine (SC)
- BIOLOGICAL Modified Live Tetravalent Chimeric Dengue Vaccine (ID)
Study Locations (1)
Missouri
- Saint Louis University - Center for Vaccine Development - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
What the finished NCT01110551 record still lists
NCT01110551 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 3,973-participant average among 9 other Dengue trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Dengue appearing as the primary indexed condition, and to 4 interventions - of which Placebo (SC) is the first listed.
NCT01110551 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT01110551 about?
NCT01110551 is a clinical study titled "Tetravalent Chimeric Dengue Vaccine Trial". The purpose of this study is to test the safety and immune response to a live attenuated dengue vaccine that could protect people against all 4 types of dengue virus. Live attenuated means that while this vaccine contains 4 live dengue viruses the viruses have been attenuated (weakened) so as not to...
What is the current status of trial NCT01110551?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2010-05. Estimated completion is 2012-12.
What conditions does trial NCT01110551 study?
This clinical trial studies the following conditions: Dengue.
What interventions are being tested in trial NCT01110551?
The interventions under investigation include: Placebo (SC) (DRUG), Placebo (ID) (DRUG), Modified Live Tetravalent Chimeric Dengue Vaccine (SC) (BIOLOGICAL), Modified Live Tetravalent Chimeric Dengue Vaccine (ID) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01110551?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01110551 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dengue
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01110551's enrollment target sits among peer trials
72 5th of 9 higher than 5 of 9 other Dengue trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dengue trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults
COMPLETED · Phase 1
-
TDENV PIV and LAV Dengue Prime-boost Strategy
COMPLETED · Phase 1
-
Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine
COMPLETED · Phase 1
-
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults
COMPLETED · Phase 1
-
ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)
COMPLETED · Phase 1
-
Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia